Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mirum Pharmaceuticals (MIRM) EPS (Basic): 2020-2025

Historic EPS (Basic) for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Sep 2025 value amounting to $0.06.

  • Mirum Pharmaceuticals' EPS (Basic) rose 120.00% to $0.06 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.85, marking a year-over-year increase of 59.13%. This contributed to the annual value of -$1.85 for FY2024, which is 53.75% up from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported EPS (Basic) of $0.06 as of Q3 2025, which was up 150.00% from -$0.12 recorded in Q2 2025.
  • Mirum Pharmaceuticals' EPS (Basic)'s 5-year high stood at $1.91 during Q4 2021, with a 5-year trough of -$1.94 in Q2 2023.
  • In the last 3 years, Mirum Pharmaceuticals' EPS (Basic) had a median value of -$0.52 in 2024 and averaged -$0.57.
  • In the last 5 years, Mirum Pharmaceuticals' EPS (Basic) soared by 232.64% in 2021 and then slumped by 151.31% in 2022.
  • Mirum Pharmaceuticals' EPS (Basic) (Quarterly) stood at $1.91 in 2021, then slumped by 151.31% to -$0.98 in 2022, then increased by 26.53% to -$0.72 in 2023, then surged by 31.94% to -$0.49 in 2024, then skyrocketed by 120.00% to $0.06 in 2025.
  • Its EPS (Basic) was $0.06 in Q3 2025, compared to -$0.12 in Q2 2025 and -$0.30 in Q1 2025.